US and EU filings for Astellas' first-in-class OAB drug mirabegron
This article was originally published in Scrip
Executive Summary
Astellas has filed for the approval of its first-in-class beta-3 adrenoceptor agonist mirabegron in the US and EU markets for the treatment of overactive bladder (OAB), in line with the company's guidance that it would do so by the end of the fiscal second quarter on 30 September.